Literature DB >> 3026627

Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin.

R J Motzer, G J Bosl, K Tauer, R Golbey.   

Abstract

A phase II trial of carboplatin was conducted in 22 patients with advanced germ cell tumors refractory to cisplatin-based chemotherapy. Twenty of 22 patients were evaluable for toxicity and response. Two partial responses and one minor response were seen. The major toxic effect was myelosuppression. Carboplatin has antitumor activity in patients with advanced germ cell tumors refractory to cisplatin, and phase II and III studies of combination chemotherapy are indicated.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3026627

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  5 in total

1.  Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT.

Authors:  B A Murphy; R J Motzer; G J Bosl
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

2.  Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract.

Authors:  H Akaza; M Hagiwara; N Deguchi; T Kawai; Y Satomi; T Matsuda; T Miki; T Ueda; T Kotake; H Tazaki
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency.

Authors:  R J Motzer; D Niedzwiecki; M Isaacs; C Menendez-Botet; W P Tong; C Flombaum; H I Scher; G J Bosl
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.

Authors:  A D Elias; L J Ayash; J P Eder; C Wheeler; J Deary; L Weissman; M Hunt; J Critchlow; L Schnipper; E Frei
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 5.  Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.

Authors:  A J Wagstaff; A Ward; P Benfield; R C Heel
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.